Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?